

# Drug Utilization Review Board

## Meeting Minutes

**Thursday, June 13, 2019**  
**7:15 a.m. to 8:30 a.m.**  
**Cannon Health Building**  
**Room 125**

**Board Members Present:**

Kumar Shah, MSc, PEng, Board Chair  
Eric Cannon, PharmD, FAMCP  
Jennifer Brinton, MD  
Judith Turner, DVM, PharmD  
Katherine Smith, PharmD

Kyle Kitchen, PharmD  
Michelle Hoffman, MD  
Neal Catalano, PharmD  
Sharon Weinstein, MD  
Susan Siegfried, MD

**Board Members Excused:**

**Dept. of Health/Div. of Health Care Financing Staff Present:**

Jennifer Strohecker, PharmD  
Bryan Larson, PharmD  
Joe Busby, RPh, MBA

Andrea Rico, CPhT, CPC  
Spencer Millier, CPhT

**University of Utah Drug Regimen Review Center Staff Presenter:**

Joann LaFleur, PharmD

**Other Individuals Present:**

Jennifer Lauper, BMS  
Jason Bott, Lilly  
Danny McNatty, J&J  
Laura Hill, Abbvie  
Angela Hill, U of U  
Stephen Kim, U of U  
Lauren Heath, U of U

Charissa Anne, J&J  
Bessie Harper, J&J  
Valerie Gonzales, U of U  
Lori Howarth, Bayer  
Elena Martinez, U of U  
Don McCaffrey, Vertex

**Meeting conducted by: Kumar Shah**

---

1. **Welcome & Housekeeping:** Kumar Shah opened the meeting, reminded everyone to sign the rosters, and announced a quorum.
2. **Review and Approval of March Minutes:** Michelle Hoffman made a motion to Approve the minutes from March. Jennifer Brinton seconded the motion. Nine in favor, one abstained, motion passed.
3. **Ketamine and Esketamine:**
  - a. **Information:** Dr. Paul Carlson was not able to attend for guest presentation.
  - b. **Public Comment:** Danny McNatty from Johnson and Johnson presented clinical

information on Spravato including indications, dosing and administration, clinical trial data.

- c. **Board Discussion:** Sharon Weinstein asked about the high placebo rate. Danny McNatty responded stating the placebo response was about 30-40% in the trials. Sharon Weinstein stated that was pretty standard in clinical trials. Danny McNatty clarified it was high relative to clinical practice. Elena Gonzales asked what medications were used in combination with Spravato. Danny McNatty responded stating the four medications that could be used were escitalopram, sertraline, duloxetine, and venlafaxine. Susan Siegfried asked a questions regarding use of other psychotropic medications that may elevate blood pressure, and whether or not they are relatively contraindicated. Danny McNatty responded stating this would be part of the clinical judgement including other medications that may be sedating such as benzodiazepines, opioids, etc. Bryan Larson stated the medication may only be distributed through the REMS program, and inquired if any pharmacy could participate in the REMS program or only designated specialty pharmacies. Danny McNatty responded stating pharmacies must be signed up through the REMS program, and the medication must be dispensed to the site of care, not to the patient. Additionally, this medication runs through the specialty pharmacy network based on the distribution model. A board member inquired as to whether or not there were any registered sites of care in Utah yet. Danny McNatty responded directing providers to [spravatorems.com](http://spravatorems.com) for the treatment locator. Joe Busby inquired as to whether Valley Mental Health was registered as a treatment center. Danny McNatty stated he would need to look it up. Joe Busby asked for recommendation on length of therapy for Spravato. Danny McNatty responded stating the FDA and Janssen decided not to include a duration of therapy in the label. Median duration of therapy in the randomized withdrawal trials was about eight months, and in clinical practice an adequate trial is needed before deciding whether or not the patient should continue using a medication. Danny McNatty also stated currently there is no long term treatment data. Sharon Weinstein inquired as to whether or not this medication was being explored for pain, Danny McNatty responded stating not at this time. Jennifer Strohecker invited the board to review and discuss the pharmacy prior authorization for Spravato.
- d. **Board Action:** Eric Cannon made a motion to modify the Spravato PA criteria to state appropriate trial and failure (due to lack of effect or unacceptable adverse reactions) of at least two preferred agents with two mechanisms of action. Sharon seconded the motions. Unanimous approval. Michelle Hoffman made a motion to change the re-authorization criteria to six months. Susan Siegfried seconded. Unanimous approval.

#### 4. **Nine Month Review:**

- a. **Information:** Consolidation of New to Market Drugs Prior Authorization Form, Brand Name Prior Authorization Form, Off-label Use Prior Authorization Form, Non-Preferred Authorization Request Forms. Review of Opioid Prior

Authorization Form

- b. Public Comment:** None
  - c. Board Discussion:** The board discussed adding the information from the Off Label Use prior authorization form. Additionally, the board recommends an avenue for literature to be submitted for pediatric patients in the absence of study data and peer reviewed literature, suggesting clinical practice guidelines.
  - d. Board Action:** Susan Siegfried made a motion to add the off label use criteria to the prior authorization form. Jennifer Brinton seconded. Unanimous approval. Sharon Weinstein made a motion to include for pediatric patients *ANY* literature and/or clinical practice guidelines that are available for off label treatment. Motion was seconded. Unanimous approval.
5. **High Dose Opioid Intervention Presentation:**
- a. Information:** Jennifer Strohecker presented information and data on High Dose Opioid Interventions for Utah Medicaid fee-for-service recipients.
6. **Public Meeting Adjourned:** Eric Cannon motioned to close the meeting. Unanimous Approval.
7. **The next meeting scheduled for** Thursday, July 11, 2019 Medicaid Pharmacy Quality Measure Performance.

---

Audio recordings of DUR meetings are available online at:  
<https://medicaid.utah.gov/pharmacy/drug-utilization-review-board?p=DUR%20Board%20Audio%20Recordings/>